$2.4 Billion Actos Bladder Cancer Settlement Explained

Popular radio program Ringler Radio, conducted by the nation’s largest structured settlement company, Ringler Associates, welcomes Beasley Allen principal Frank Woodson to discuss the recent $2.4 billion settlement over the diabetes drug Actos.

Actos (pioglitazone), manufactured by Takeda Pharmaceuticals and distributed by Eli Lilly and Company, has been under FDA review since September 2010. In June 2011, the FDA issued a warning for Actos, while at the same time drug regulators in France and Germany suspended use of the drug, after it was linked to an increased risk for the development of bladder cancer. Despite the risk of developing bladder cancer, Takeda raked in nearly $16 billion off of Actos prior to going generic in late 2012.

For more information on Actos and other litigation Beasley Allen is involved with, visit our website at www.BeasleyAllen.com.


We're here to help!

We live by our creed of “helping those who need it most” and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked * may be required for submission.


Wonderful to work with

Beasley Allen did a great job with my case. They were wonderful to work with. They were available by phone when I needed them, treated me with the utmost respect and worked hard on my behalf. If a need arises in the future, I would definitely call on them again.

—Geraldine